Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening
This article was originally published in PharmAsia News
Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.
You may also be interested in...
H3 Biomedicine is using publicly available cancer genomics data to discover compounds that could treat small subsets of patients.